COMPANY PROFILE

Aortyx

Aortyx has developed a biomimetic bioresorbable adhesive patch to treat aortic dissections. It helps to stop false lumen blood flow, promotes natural repair and bio integration

Teià, SpainFounded 2018Health Tech & Medtech

Valuation $50–100M Last recorded · 2025

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Aortyx

Developer of endovascular devices intended to treat vascular diseases. The company's devices focus on tissue regeneration by mimicking the aorta biomechanical environment and provide a suitable milieu for cell migration and proliferation in a bioresorbable platform that minimizes differences with the natural dynamics of the aorta, enabling professionals to treat vascular diseases in an efficient manner. Keywords: Healthcare Devices, Services, Supplies, Aortic Disease Treatment, Biomechanical Environment, Cell Migration, Cell Proliferation, Endovascular Device, Vascular Disease.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2018
Headquarters: Teià, Spain
Employees: 30
Open positions: 2
Dealroom signal: 84.2/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Surgery, Cardiology and cardiovascular, Tissue Engineering, Regenerative Medicine, Spinout, EIC, Headstart (EIT Health), European Health Catapult (EIT Health)
Technology: Deep Tech, Nanotech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jun 2025	$15M	$61M	CDTI · Nara Capital · Ship2B Ventures · Banco Sabadell	↗
SUPPORT PROGRAM✓Other financing	Jan 2022	$0	—	EIT Health	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Aortyx website traffic

Latest recorded traffic for Aortyx is 1.1K monthly website visits, up 39.2% over the last three months. Aortyx's team grew 11.1% over the past year.

Latest monthly visits1.1K 3-month web change+39.2% 1-year team growth+11.1%

Monthly website visitsOct 2018–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Research And Development EngineerBarcelona, Catalonia, Spain · Other · Aug 26, 2026 Quality Affairs SpecialistBarcelona, Catalonia, Spain · Other · Aug 26, 2026 Regulatory Affairs SpecialistBarcelona, Catalonia, Spain · Legal · Aug 26, 2026 Regulatory and Clinical Affairs DirectorEsplugues de Llobregat, Catalonia, Spain · Other · Jul 22, 2026 Auxiliar de laboratoriEsplugues de Llobregat, Catalonia, Spain · Human Resources · Jun 19, 2026

5 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATADmit TherapeuticsEpigenetic blood test for early Alzheimer's prognosis	Esplugues de Llobregat, Spain	Operational	14	$9M	$24M
KRKribaNon-invasive screening and monitoring of serous fluids infections of the body	Madrid, Spain	Operational
ABArthex BiotechFocused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs	Paterna, Spain	Operational
IPIlya PharmaIlya Pharma develops immune-cell therapies. The company's biological medicine uses lactic acid bacteria as vectors to deliver biological drugs on-site to skin wounds or the GI tract	Uppsala kommun, Sweden	Operational
PEPeptomycFoundational anti-MYC mini-proteins for cancer treatment	Barcelona, Spain	Operational
GRGanymed RoboticsGanymed retools orthopaedics with robotics. Their product is a compact, ergonomic, and cost-effective joint-replacement device. The robot's intelligence and perception are driven by computer vision	Paris, France	Operational
CRCroivalveTreating Heart Valve Disease	Dublin, Ireland	Operational
AMAuriGen MedicalCommitted to delivering hope to the heart of our patients	Galway, Ireland	Operational